Analysts Raise 12-Month Targets for Cincinnati Financial and Adaptive
Analysts lifted average 12-month targets for both companies. The implied upside is about 16% for Cincinnati Financial and 9% for Adaptive Biotechnologies.
- published
- in the api
- on the website
- updated
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
TradingView reports that Cincinnati Financial Corporation’s average 12-month price target, based on estimates from 6 analysts, increased from $187.83 to $188.83. Forecasts range from $171 to $200 per share. Relative to the Oct. 9 closing price, the revised target indicates approximately 16% potential upside.
The consensus rating shifted to “Buy” among 11 analysts covering the stock, comprising 4 Buys, 7 Holds and 0 Sells. FactSet is identified as the source of the reference data.
According to Newsmetry API, the average target for Adaptive Biotechnologies Corporation, based on estimates from 8 analysts, rose from $28.31 to $28.94. Forecasts span $21 to $35 per share, while the updated target implies approximately 9% upside from the Oct. 9 close. The “Buy” consensus remains in place among 9 covering analysts, with 8 Buys, 1 Hold and 0 Sells.
why it matters
The revisions show how analysts’ current estimates changed for the two stocks. Target prices and ratings describe market consensus and are not personal investment advice.
instruments
sources
- Cincinnati Financial Corporation Stock 12‑Month Price Target Raised to $188.83, Implies 16% Upside — TradingView, 12 October 2026 at 13:20 UTC
- Adaptive Biotechnologies Corporation Stock 12‑Month Price Target Raised to $28.94, Implies 9% Upside — Newsmetry API, 12 October 2026 at 16:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗